Australia's Radiopharm Theranostics soars on FDA nod for osteosarcoma treatment

Radiopharm Theranostics

16/09/2022 04:35

** Shares of Radiopharm Theranostics  RAD.AX  jump as much
as 15.2% to A$0.19, set to mark their best day since July 18, if
gains hold
    ** Radiopharmaceutical products maker says its DUNP19
technology for the treatment of osteosarcoma has been granted
Rare Pediatric Disease (RPD) status by the US Food & Drug
Administration (FDA)  urn:newsml:reuters.com:*:nTUE58Z7PM
    ** RPD status allows development of drugs with the potential
to treat serious, rare pediatric diseases
    ** Under the status, FDA issues a priority review voucher
during marketing authorization to cos 
    ** Stock hits highest since Aug. 30 
    ** Stock down 58.2% this year, as of last close


 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com;))